Poly Medicure Limited has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors has recommended a dividend of ₹3.50 per equity share (70%) for the financial year 2025-26. The company also confirmed the re-appointment of its internal auditors and provided updates on recent business acquisitions and strategic growth initiatives implemented during the year.
Financial Performance Overview
For the financial year ended March 31, 2026, Poly Medicure Limited reported robust growth. On a consolidated basis, the total income reached ₹1,99,534.14 lacs for the year. The consolidated net profit attributable to equity holders of the parent for the year stood at ₹32,213.96 lacs. The company’s focus on operational efficiency and strategic investments continues to drive its performance in the medical devices sector.
Dividend Recommendation
The Board of Directors has recommended a final dividend of ₹3.50 per equity share, representing 70% of the face value of ₹5 each for the financial year 2025-26. This dividend is subject to the approval of shareholders at the upcoming Annual General Meeting.
Strategic Acquisitions and Growth
The company continues to expand its global footprint. During the year, the Group acquired 90% economic rights in the Pendracare Group and also completed the final acquisition accounting for the Citieffe group. Furthermore, the company is in the process of acquiring 100% equity in Himalayan Mineral Water Private Limited, following the approval of the resolution plan by the NCLT.
Operational Updates
The Board has re-appointed PricewaterhouseCoopers Services LLP and M/s Oswal Sunil & Co. Chartered Accountants as internal auditors for the financial year 2026-27. Additionally, the company successfully utilized its QIP proceeds to fund inorganic initiatives, capital expenditure, and general corporate purposes, strengthening its balance sheet for future operational demands.
Source: BSE
